These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1127 related articles for article (PubMed ID: 22440498)
1. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study. Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498 [TBL] [Abstract][Full Text] [Related]
2. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials. Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M; JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631 [TBL] [Abstract][Full Text] [Related]
3. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). Spaulding C; Teiger E; Commeau P; Varenne O; Bramucci E; Slama M; Beatt K; Tirouvanziam A; Polonski L; Stella PR; Clugston R; Fajadet J; de Boisgelin X; Bode C; Carrié D; Erglis A; Merkely B; Hosten S; Cebrian A; Wang P; Stoll HP; Henry P JACC Cardiovasc Interv; 2011 Jan; 4(1):14-23. PubMed ID: 21251624 [TBL] [Abstract][Full Text] [Related]
4. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries. Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW; JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464 [TBL] [Abstract][Full Text] [Related]
6. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. Valgimigli M; Percoco G; Malagutti P; Campo G; Ferrari F; Barbieri D; Cicchitelli G; McFadden EP; Merlini F; Ansani L; Guardigli G; Bettini A; Parrinello G; Boersma E; Ferrari R; JAMA; 2005 May; 293(17):2109-17. PubMed ID: 15870414 [TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial. Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Stanco G; Rosato G; Suryapranata H; De Luca G JACC Cardiovasc Interv; 2014 Aug; 7(8):849-56. PubMed ID: 25147029 [TBL] [Abstract][Full Text] [Related]
8. Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials. Valgimigli M; Campo G; Malagutti P; Anselmi M; Bolognese L; Ribichini F; Boccuzzi G; de Cesare N; Rodriguez AE; Russo F; Moreno R; Biondi-Zoccai G; Penzo C; Díaz Fernández JF; Parrinello G; Ferrari R JACC Cardiovasc Interv; 2011 Jan; 4(1):51-62. PubMed ID: 21251629 [TBL] [Abstract][Full Text] [Related]
9. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. Vink MA; Dirksen MT; Suttorp MJ; Tijssen JG; van Etten J; Patterson MS; Slagboom T; Kiemeneij F; Laarman GJ JACC Cardiovasc Interv; 2011 Jan; 4(1):24-9. PubMed ID: 21251625 [TBL] [Abstract][Full Text] [Related]
10. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. Di Lorenzo E; De Luca G; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G JACC Cardiovasc Interv; 2009 Jun; 2(6):515-23. PubMed ID: 19539255 [TBL] [Abstract][Full Text] [Related]
11. Gender differences in long-term outcome after primary percutaneous intervention for ST-segment elevation myocardial infarction. Wijnbergen I; Tijssen J; van 't Veer M; Michels R; Pijls NH Catheter Cardiovasc Interv; 2013 Sep; 82(3):379-84. PubMed ID: 23553888 [TBL] [Abstract][Full Text] [Related]
12. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial. Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA; JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342 [TBL] [Abstract][Full Text] [Related]
13. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698 [TBL] [Abstract][Full Text] [Related]
14. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R; JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998 [TBL] [Abstract][Full Text] [Related]
15. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting. Chacko R; Mulhearn M; Novack V; Novack L; Mauri L; Cohen SA; Moses J; Leon MB; Cutlip DE JACC Cardiovasc Interv; 2009 Jun; 2(6):498-503. PubMed ID: 19539252 [TBL] [Abstract][Full Text] [Related]
16. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. Saltzman AJ; Stone GW; Claessen BE; Narula A; Leon-Reyes S; Weisz G; Brodie B; Witzenbichler B; Guagliumi G; Kornowski R; Dudek D; Metzger DC; Lansky AJ; Nikolsky E; Dangas GD; Mehran R JACC Cardiovasc Interv; 2011 Sep; 4(9):1011-9. PubMed ID: 21939942 [TBL] [Abstract][Full Text] [Related]
17. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study. Valgimigli M; Campo G; Arcozzi C; Malagutti P; Carletti R; Ferrari F; Barbieri D; Parrinello G; Percoco G; Ferrari R J Am Coll Cardiol; 2007 Jul; 50(2):138-45. PubMed ID: 17616297 [TBL] [Abstract][Full Text] [Related]
18. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial. Sabaté M; Brugaletta S; Cequier A; Iñiguez A; Serra A; Hernádez-Antolín R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vázquez N; Backx B; Serruys PW JACC Cardiovasc Interv; 2014 Jan; 7(1):64-71. PubMed ID: 24332423 [TBL] [Abstract][Full Text] [Related]
19. Clinical impact of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized clinical trials. Piscione F; Piccolo R; Cassese S; Galasso G; Chiariello M Catheter Cardiovasc Interv; 2009 Aug; 74(2):323-32. PubMed ID: 19360858 [TBL] [Abstract][Full Text] [Related]
20. Five-year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus-eluting stents: insights from the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital-(Research) Registry. Shen ZJ; García-García HM; Garg S; Onuma Y; Schenkeveld L; van Domburg RT; Serruys PW; Catheter Cardiovasc Interv; 2009 Dec; 74(7):979-86. PubMed ID: 19753636 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]